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Editorial on the Research Topic
Personal Genomes: Accessing, Sharing, and Interpretation
Over the past few years we have witnessed a number of advances in the personal genomics space
including (a) more affordable sequencing technology, (b) mainstreaming of genomics in healthcare
systems, (c) augmented sharing of genomic data, and (d) increased demand for direct-to-consumer
genetic testing. All of these developments have brought us closer to the long-awaited genomics
revolution. This genomics revolution is not exempt from challenges, in part amplified by lack
of standards (ethical, legal, and technological), slow translation of knowledge to the clinic, and
unequal access of personal genome benefits for all.
As the vast majority of reference data in public databases continue to be of European ancestries,
existing health disparities between rich and poor are likely to continue. In parallel, access to direct-
to-consumer personal genetic testing continues to increase the public’s appetite for genotyping and
ancestry testing, resulting in greater number of enquiries with clinicians and public healthcare
systems. This has left many medical professionals unprepared and unable to harness the wave
of patient-focused healthcare and demand for data sharing—data sharing which is crucial for
establishing better, more precise tools for diagnosis and treatment. However, sharing also opens
the door for privacy concerns as secure access of genome data and metadata cannot always be
guaranteed. Increased legal protection and institutional support are likely to keep promoting
positive impact for diverse participation.
On April 11–12, 2019, we helped organize the First Personal Genomes Conference at the
Wellcome Genome Campus, Hinxton, UK, to discuss issues around personal genomic data access,
sharing, and interpretation (Rubin and Glusman, 2019). In this Research Topic in Frontiers in
Genetics, we collected a selection of representative research related to the Conference’s topics
revolving around the themes of (a) personal genetic testing, (b) interpretation of personal genomes,
(c) personal genomics citizen science, (d) return of data to genome research participants, (e) data
protection, privacy and the ethics of data sharing, and (f) clinical perspective—from patients to
the public.
In our Research Topic, Du and Wang describe how the direct-to-consumer market in China
has been particularly buoyant in recent years, with many providers offering multiple channels for
purchasing genetic testing products. They argue, however, that a regulatory vacuum exists in how
to obtain valid informed consent, and protect customers’ genetic data from access by third parties.
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In India, Pemmasani et al. stress the need for existing data
reference repositories to expand their variant data information,
offering non-European personal genomes equitable access to
resources and tools for their interpretation. Folkersen et al.
present Impute.me, an open source tool for analyzing direct-to-
consumer genetic data. With tools such as Impute.me anyone
in the world can calculate and interpret polygenic risk scores
free of charge. Guerra-Assunção et al. present another tool,
GenomeChronicler, that uses open access Personal Genome
Project (PGP-UKConsortium, 2018) data to generate reports (for
research use only) that include information relating to possibly
beneficial and harmful variants as well as ancestry. Mehandziska
et al. show an analytical pipeline to effectively report variants
of unknown significance, which to date remain among the most
challenging types of variants to interpret. Corpas et al. illustrate
how existing tools and resources can be leveraged for whole
genome analysis when combined. Their extensive battery of
analyses for a single family provides a use case for clinicians
on how to develop healthcare plans for the individual, based on
genetic and other healthcare data.
Access to raw personal genomic data in clinical settings
is becoming commonplace in many European nations.
Narayanasamy et al. explored personal genome access policies
and practices from a pool of European sequencing institutions
engaged in generating massive amounts of sequencing data.
They report a generalized lack of clear policies and processes
for raw genomic data retention and access among large
sequencing facilities. Wallace et al. argue that even when raw
data are available, enabling genomic and biomedical data to
be accessed and shared for secondary research purposes is
not always straightforward for existing “legacy” datasets. A
filter used by researchers could help determine the extent to
which a given dataset can be shared. Ahmed and Shabani
suggest that data sharing promoted by DNA marketplaces
raises concerns about consent and privacy, and may have
implications for public-funded research that does not offer
incentives to share. Yet, for parents of children suffering from
rare and common diseases, there are powerful incentives to
share whole genome sequencing data. Beauvais et al. provide
recommendations for healthcare professionals in the clinical
and research contexts when faced with sharing genomic data on
parental request for a child’s raw genomic data. Wöhlke et al.
contribute to this debate by suggesting that lay people’s sharing
perceptions are important because they affect both their interest
in undertaking genetic testing as well as their interpretations of
test results. Their survey on personal sharing preferences in both
Germany and Italy shows a relatively high willingness among
participants to share information with their social circle, but an
overall strong reluctance to share data with certain institutions
(such as employers, health insurance) due to fear of genetic
discrimination. In Korea, however, Kim et al. found that public
interest toward establishing a citizen participation cohort is
very high.
In conclusion, we observe that although general access to
personal genome data is becoming more widespread, the benefits
of such advances are being deployed unevenly. Tools are being
implemented that help facilitate the interpretation of personal
genomic data and their increased, more secure sharing. We see
these advances being undertaken both by academic and industry
sectors. But a number of ethical challenges persist, including
how to return data to participants in different regions of the
world, or how to access direct-to-consumer services and raw
data for personal genome analysis, which still remain biased
depending on the individual’s local jurisdiction. It is our wish to
raise awareness about these hurdles and to bring all stakeholders
involved into fruitful discussions to promote greater access to the
benefits of personal genomics for all.
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